Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Techno DrugsDHA:TECHNODRUG -2.27%37 ROE % is 3.91% as of Mar. 2026, which is 49% below its 10-year median of 7.68. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review. Among 937 Drug Manufacturers companies, Techno Drugs ranks worse than 53.68% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Techno Drugs's annualized net income for the quarter that ended in Mar. 2026 was BDT161 Mil. Techno Drugs's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was BDT4,122 Mil. Therefore, Techno Drugs's annualized ROE % for the quarter that ended in Mar. 2026 was 3.91%.
The historical rank and industry rank for Techno Drugs's ROE % or its related term are showing as below:
DHA:TECHNODRUG'
s ROE % Range Over the Past 10 Years
Min: 4.97 Med: 7.68 Max: 8.9
Current: 4.97
During the past 2 years, Techno Drugs's highest ROE % was 8.90%. The lowest was 4.97%. And the median was 7.68%.
DHA:TECHNODRUG's ROE % is ranked worse than 53.68% of 937
companies
in the Drug Manufacturers industry
Industry Median: 6.04
vs DHA:TECHNODRUG: 4.97
Techno Drugs (DHA:TECHNODRUG) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Techno Drugs ROE % Related Terms
Techno Drugs ROE % Historical Data
* Premium members only.
The historical data trend for Techno Drugs's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:TECHNODRUG vs ZTS, UTHR, VTRS: ROE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Techno Drugs ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's ROE % distribution charts can be found below:
* The bar in red indicates where Techno Drugs's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Techno Drugs (DHA:TECHNODRUG) has a ROE % of 3.91% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Techno Drugs and its competitors. This is 49% below median its historical median of 7.68. Over the past decade, Techno Drugs' ROE % has ranged from 4.97 to 8.90. According to the industry distribution chart, Techno Drugs ranks #503 out of 937 companies in the Drug Manufacturers industry, placing it in the top 53.7%.
Is Techno Drugs' ROE % too high?
Techno Drugs' current ROE % of 3.91% is 49% below median its 10-year median of 7.68. Over the past 10 years, this metric has ranged from a low of 4.97 to a high of 8.90. The Drug Manufacturers industry median ROE % is 6.04. Techno Drugs' value of 3.91% is 35.3% below this industry median. Based on the distribution chart, Techno Drugs ranks #503 out of 937 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Techno Drugs ranks #503 out of 937 companies for ROE %. This places Techno Drugs in the lower half of its industry. The industry median ROE % is 6.04. Techno Drugs' value of 3.91% is 35.3% below this benchmark. Historically, Techno Drugs' own ROE % has ranged from 4.97 to 8.90 over the past decade. While the company's 10-year median is 7.68 vs. the industry median of 6.04, Techno Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.04, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Techno Drugs's current ROE % of 3.91% is 35.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Techno Drugs and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Techno Drugs's current ROE % is 3.91%, which is 49% below median its own 10-year median of 7.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current ROE % of 3.91%. The current ROE % is 3.91%, which is 49% below median its 10-year median of 7.68 and 35.3% below the Drug Manufacturers industry median of 6.04. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current ROE % is 3.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
